Gilead to buy biotech firm Ouro Medicines in over $2 billion deal
By Thomson ReutersMar 23, 2026 | 5:27 PM
March 23 (Reuters) – Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth up to $2.18 billion.
Comments